TITLE

Review of recent evidence: Potential interaction between clopidogrel and proton pump inhibitors

AUTHOR(S)
Last, Esther J.; Sheehan, Amy Heck
PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/1/2009, Vol. 66 Issue 23, p2117
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. Recent evidence of a potential interaction between clopidogrel and proton pump inhibitors (PPIs) is discussed. Summary. The American College of Cardiology and the American Heart Association recommend use of gastroprotective agents, specifically PPIs, in patients receiving aspirin, a thienopyridine, or the combination who have an increased risk for recurrent gastrointestinal bleeding. Available evidence from one small, shortterm, randomized, double-blind trial evaluating platelet aggregation and several observational studies suggests that there is a potential for a clinically significant interaction between clopidogrel and PPIs. A post hoc analysis of a large, randomized, double-blind trial found no evidence of a clinically significant drug interaction at 28 days, though a significant difference was observed at one year. The authors concluded that the use of PPIs, regardless of clopidogrel use, increases the risk of adverse cardiovascular events. Conclusion. Although data are limited, observational studies and prospective trials involving surrogate markers of platelet reactivity suggest a clinically significant interaction between clopidogrel and PPIs. Until further studies are completed to delineate the specifics of the interaction between clopidogrel and PPIs, the risks and benefits of concomitant treatment should be carefully weighed to determine the most appropriate treatment for each individual patient.
ACCESSION #
45238697

 

Related Articles

  • Expert consensus document offers suggestions on concomitant PPI, antiplatelet drug use.  // Hem/Onc Today;11/25/2010, Vol. 11 Issue 22, p40 

    The article focuses on the expert consensus document about the concomitant use of proton pump inhibitor and thienopyridines issued by the American College of Cardiology, American College of Gastroenterology and the American Heart Association.

  • Consensus on the use of PPIs and antiplatelets.  // Reactions Weekly;1/29/2011, Issue 1336, p1 

    This article focuses on a document released by the American College of Cardiology, American College of Gastroenterology, and the American Heart Association which claims that it is appropriate to use proton pump inhibitors (PPIs) in patients receiving antiplatelets who are at risk for...

  • PPIs reduce clopidogrel-induced GI bleeding without reducing efficacy.  // Reactions Weekly;5/15/2010, Issue 1301, p2 

    This article reports on a study on the use of proton pump inhibitors (PPIs) in combination with clopidogrel to reduce the risk of serious gastrointestinal (GI) bleeding.

  • Perioperative risk. Wertheim, William A. // Geriatrics;Jul2000, Vol. 55 Issue 7, p61 

    Examines the guidelines of the American College of Cardiology and the American Heart Association regarding the assessment and perioperative risk management of patients undergoing noncardiac surgery. Myths about surgery endure; Validity of the guidelines; Case scenario and resolution on a...

  • INTERNAL MEDICINE. Naunton, Mark // Journal of Pharmacy Practice & Research;2009, Vol. 39 Issue 4, p321 

    The article presents abstracts on internal medicine research topics which include the resolution of osteonecrosis of the jaw after therapy with teriparatide, the efficacy of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome and the use of omega-3 and sertraline in...

  • THE EFFECTS OF PROTON PUMP INHIBITORS ON CLOPIDOGREL EFFICACY IN PATIENTS WITH ACS THROUGH PCI IN CHINA.  // Heart;Oct2010, pA135 

    An abstract of the article "The Effects of Proton Pump Inhibitors on Clopidogrel Efficacy in Patients With ACS Through PCI in China" by Zhao Ming and colleagues is presented.

  • PPIs and Clopidogrel: Do We Have to Worry?  // Critical Care Alert;Dec2009 Clinical Briefs in Primary, p23 

    The article focuses on the data which suggested that proton pump inhibitors (PPIs) should be avoided when treating acute coronary syndromes with clopidogrel or prasugrel.

  • PPI-clopidogrel mix more than doubles risk of death.  // Pulse;3/17/2010, Vol. 70 Issue 9, p11 

    The article reports on a study that showed co-prescribing proton pump inhibitors (PPIs) and clopidogrel more than double the risk of death in stroke patients.

  • Adverse Reaction Research.  // Reactions Weekly;10/29/2011, Issue 1375, p4 

    The article reports that more patients treated with clopidogrel are also receiving CYP2C19 inhibitors, such as proton pump inhibitors.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics